1	Over	_	_	IN	_	_	_	_	_
2	the	_	_	DT	_	_	_	_	_
3	last	_	_	JJ	_	_	_	_	_
4	few	_	_	JJ	_	_	_	_	_
5	decades	_	_	NNS	_	_	_	_	_
6	,	_	_	,	_	_	_	_	_
7	accumulating	_	_	VBG	_	_	_	_	_
8	evidence	_	_	NN	_	_	_	_	_
9	has	_	_	VBZ	_	_	_	_	_
10	demonstrated	_	_	VBN	_	_	_	_	_
11	that	_	_	IN	_	_	_	_	_
12	numerous	_	_	JJ	_	_	_	_	_
13	Interferon	_	_	NNP	_	_	_	_	_
14	(	_	_	-LRB-	_	_	_	_	_
15	IFN	_	_	NNP	_	_	_	_	_
16	)	_	_	-RRB-	_	_	_	_	_
17	stimulate	_	_	VBP	_	_	_	_	_
18	genes	_	_	NNS	_	_	_	_	_
19	(	_	_	-LRB-	_	_	_	_	_
20	ISGs	_	_	NNS	_	_	_	_	_
21	)	_	_	-RRB-	_	_	_	_	_
22	can	_	_	MD	_	_	_	_	_
23	be	_	_	VB	_	_	_	_	_
24	directly	_	_	RB	_	_	_	_	_
25	upregulated	_	_	VBN	_	_	_	_	_
26	following	_	_	VBG	_	_	_	_	_
27	virus	_	_	NN	_	_	_	_	_
28	infection	_	_	NN	_	_	_	_	_
29	independent	_	_	JJ	_	_	_	_	_
30	of	_	_	IN	_	_	_	_	_
31	IFN	_	_	NN	_	_	_	_	_
32	signaling	_	_	VBG	_	_	_	_	_
33	.	_	_	.	_	_	_	_	_


1	Indeed	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	whereas	_	_	IN	_	_	_	_	_
4	typical	_	_	JJ	_	_	_	_	_
5	ISGs	_	_	NNS	_	_	_	_	_
6	are	_	_	VBP	_	_	_	_	_
7	driven	_	_	VBN	_	_	_	_	_
8	by	_	_	IN	_	_	_	_	_
9	JAK-STAT	_	_	NN	_	_	_	_	_
10	signaling	_	_	NN	_	_	_	_	_
11	,	_	_	,	_	_	_	_	_
12	other	_	_	JJ	_	_	_	_	_
13	virally-stimulated	_	_	JJ	_	_	_	_	_
14	genes	_	_	NNS	_	_	_	_	_
15	are	_	_	VBP	_	_	_	_	_
16	upregulated	_	_	VBN	_	_	_	_	_
17	through	_	_	IN	_	_	_	_	_
18	the	_	_	DT	_	_	_	_	_
19	IRF3	_	_	NNP	_	_	_	_	_
20	and	_	_	CC	_	_	_	_	_
21	NF-κB	_	_	NNP	_	_	_	_	_
22	pathways	_	_	NNS	_	_	_	_	_
23	.	_	_	.	_	_	_	_	_


1	These	_	_	DT	_	_	_	_	_
2	genes	_	_	NNS	_	_	_	_	_
3	can	_	_	MD	_	_	_	_	_
4	be	_	_	VB	_	_	_	_	_
5	called	_	_	VBN	_	_	_	_	_
6	virus	_	_	NN	_	_	_	_	_
7	stimulated	_	_	VBN	_	_	_	_	_
8	genes	_	_	NNS	_	_	_	_	_
9	(	_	_	-LRB-	_	_	_	_	_
10	VSGs	_	_	NNPS	_	_	_	_	_
11	)	_	_	-RRB-	_	_	_	_	_
12	,	_	_	,	_	_	_	_	_
13	and	_	_	CC	_	_	_	_	_
14	IFNs	_	_	NNP	_	_	_	_	_
15	themselves	_	_	PRP	_	_	_	_	_
16	are	_	_	VBP	_	_	_	_	_
17	VSGs	_	_	NNPS	_	_	_	_	_
18	.	_	_	.	_	_	_	_	_


1	Interestingly	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	VSGs	_	_	NNPS	_	_	_	_	_
4	have	_	_	VBP	_	_	_	_	_
5	natural	_	_	JJ	_	_	_	_	_
6	anticancer	_	_	NN	_	_	_	_	_
7	activities	_	_	NNS	_	_	_	_	_
8	,	_	_	,	_	_	_	_	_
9	and	_	_	CC	_	_	_	_	_
10	they	_	_	PRP	_	_	_	_	_
11	may	_	_	MD	_	_	_	_	_
12	cause	_	_	VB	_	_	_	_	_
13	diseases	_	_	NNS	_	_	_	_	_
14	in	_	_	IN	_	_	_	_	_
15	humans	_	_	NNS	_	_	_	_	_
16	when	_	_	WRB	_	_	_	_	_
17	induced	_	_	VBN	_	_	_	_	_
18	chronically	_	_	RB	_	_	_	_	_
19	.	_	_	.	_	_	_	_	_


1	To	_	_	TO	_	_	_	_	_
2	understand	_	_	VB	_	_	_	_	_
3	their	_	_	PRP$	_	_	_	_	_
4	role	_	_	NN	_	_	_	_	_
5	in	_	_	IN	_	_	_	_	_
6	host	_	_	NN	_	_	_	_	_
7	defense	_	_	NN	_	_	_	_	_
8	and	_	_	CC	_	_	_	_	_
9	pathogenesis	_	_	NN	_	_	_	_	_
10	,	_	_	,	_	_	_	_	_
11	excellent	_	_	JJ	_	_	_	_	_
12	model	_	_	NN	_	_	_	_	_
13	systems	_	_	NNS	_	_	_	_	_
14	have	_	_	VBP	_	_	_	_	_
15	been	_	_	VBN	_	_	_	_	_
16	developed	_	_	VBN	_	_	_	_	_
17	.	_	_	.	_	_	_	_	_


1	However	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	there	_	_	EX	_	_	_	_	_
4	are	_	_	VBP	_	_	_	_	_
5	still	_	_	RB	_	_	_	_	_
6	important	_	_	JJ	_	_	_	_	_
7	gaps	_	_	NNS	_	_	_	_	_
8	in	_	_	IN	_	_	_	_	_
9	our	_	_	PRP$	_	_	_	_	_
10	understanding	_	_	NN	_	_	_	_	_
11	of	_	_	IN	_	_	_	_	_
12	VSGs	_	_	NNPS	_	_	_	_	_
13	and	_	_	CC	_	_	_	_	_
14	host	_	_	NN	_	_	_	_	_
15	defense	_	_	NN	_	_	_	_	_
16	.	_	_	.	_	_	_	_	_


1	Recently	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	RNA	_	_	NNP	_	_	_	_	_
4	sequencing	_	_	NN	_	_	_	_	_
5	techniques	_	_	NNS	_	_	_	_	_
6	have	_	_	VBP	_	_	_	_	_
7	allowed	_	_	VBN	_	_	_	_	_
8	the	_	_	DT	_	_	_	_	_
9	discovery	_	_	NN	_	_	_	_	_
10	of	_	_	IN	_	_	_	_	_
11	novel	_	_	JJ	_	_	_	_	_
12	VSGs	_	_	NNS	_	_	_	_	_
13	that	_	_	WDT	_	_	_	_	_
14	also	_	_	RB	_	_	_	_	_
15	include	_	_	VBP	_	_	_	_	_
16	non-coding	_	_	JJ	_	_	_	_	_
17	RNAs	_	_	NNS	_	_	_	_	_
18	.	_	_	.	_	_	_	_	_


1	This	_	_	DT	_	_	_	_	_
2	Special	_	_	NNP	_	_	_	_	_
3	Issue	_	_	NN	_	_	_	_	_
4	of	_	_	IN	_	_	_	_	_
5	Viruses	_	_	NNPS	_	_	_	_	_
6	will	_	_	MD	_	_	_	_	_
7	explore	_	_	VB	_	_	_	_	_
8	the	_	_	DT	_	_	_	_	_
9	impact	_	_	NN	_	_	_	_	_
10	of	_	_	IN	_	_	_	_	_
11	VSGs	_	_	NNS	_	_	_	_	_
12	on	_	_	IN	_	_	_	_	_
13	the	_	_	DT	_	_	_	_	_
14	outcome	_	_	NN	_	_	_	_	_
15	of	_	_	IN	_	_	_	_	_
16	virus	_	_	NN	_	_	_	_	_
17	infection	_	_	NN	_	_	_	_	_
18	and	_	_	CC	_	_	_	_	_
19	the	_	_	DT	_	_	_	_	_
20	role	_	_	NN	_	_	_	_	_
21	of	_	_	IN	_	_	_	_	_
22	these	_	_	DT	_	_	_	_	_
23	genes	_	_	NNS	_	_	_	_	_
24	within	_	_	IN	_	_	_	_	_
25	the	_	_	DT	_	_	_	_	_
26	infected	_	_	VBN	_	_	_	_	_
27	cells	_	_	NNS	_	_	_	_	_
28	and	_	_	CC	_	_	_	_	_
29	organism	_	_	NN	_	_	_	_	_
30	.	_	_	.	_	_	_	_	_


1	We	_	_	PRP	_	_	_	_	_
2	have	_	_	VBP	_	_	_	_	_
3	focused	_	_	VBN	_	_	_	_	_
4	on	_	_	IN	_	_	_	_	_
5	the	_	_	DT	_	_	_	_	_
6	most	_	_	RBS	_	_	_	_	_
7	recent	_	_	JJ	_	_	_	_	_
8	discoveries	_	_	NNS	_	_	_	_	_
9	in	_	_	IN	_	_	_	_	_
10	VSG	_	_	NNP	_	_	_	_	_
11	research	_	_	NN	_	_	_	_	_
12	,	_	_	,	_	_	_	_	_
13	including	_	_	VBG	_	_	_	_	_
14	the	_	_	DT	_	_	_	_	_
15	molecular	_	_	JJ	_	_	_	_	_
16	biology	_	_	NN	_	_	_	_	_
17	of	_	_	IN	_	_	_	_	_
18	related	_	_	JJ	_	_	_	_	_
19	virus	_	_	NN	_	_	_	_	_
20	–	_	_	:	_	_	_	_	_
21	host	_	_	NN	_	_	_	_	_
22	interactions	_	_	NNS	_	_	_	_	_
23	.	_	_	.	_	_	_	_	_


1	Topics	_	_	NNS	_	_	_	_	_
2	include	_	_	VBP	_	_	_	_	_
3	studies	_	_	NNS	_	_	_	_	_
4	on	_	_	IN	_	_	_	_	_
5	various	_	_	JJ	_	_	_	_	_
6	steps	_	_	NNS	_	_	_	_	_
7	of	_	_	IN	_	_	_	_	_
8	gene	_	_	NN	_	_	_	_	_
9	induction	_	_	NN	_	_	_	_	_
10	,	_	_	,	_	_	_	_	_
11	innate	_	_	JJ	_	_	_	_	_
12	immune	_	_	JJ	_	_	_	_	_
13	responses	_	_	NNS	_	_	_	_	_
14	to	_	_	TO	_	_	_	_	_
15	virus	_	_	NN	_	_	_	_	_
16	infection	_	_	NN	_	_	_	_	_
17	,	_	_	,	_	_	_	_	_
18	and	_	_	CC	_	_	_	_	_
19	the	_	_	DT	_	_	_	_	_
20	mechanisms	_	_	NNS	_	_	_	_	_
21	of	_	_	IN	_	_	_	_	_
22	virus	_	_	NN	_	_	_	_	_
23	immune	_	_	JJ	_	_	_	_	_
24	evasion	_	_	NN	_	_	_	_	_
25	of	_	_	IN	_	_	_	_	_
26	related	_	_	JJ	_	_	_	_	_
27	host	_	_	NN	_	_	_	_	_
28	defense	_	_	NN	_	_	_	_	_
29	pathways	_	_	NNS	_	_	_	_	_
30	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	clinical	_	_	JJ	_	_	_	_	_
3	presentation	_	_	NN	_	_	_	_	_
4	of	_	_	IN	_	_	_	_	_
5	VSG-driven	_	_	JJ	_	_	_	_	_
6	pathology	_	_	NN	_	_	_	_	_
7	and	_	_	CC	_	_	_	_	_
8	strategies	_	_	NNS	_	_	_	_	_
9	to	_	_	TO	_	_	_	_	_
10	use	_	_	VB	_	_	_	_	_
11	VSGs	_	_	NNS	_	_	_	_	_
12	to	_	_	TO	_	_	_	_	_
13	cure	_	_	VB	_	_	_	_	_
14	chronic	_	_	JJ	_	_	_	_	_
15	viral	_	_	JJ	_	_	_	_	_
16	infections	_	_	NNS	_	_	_	_	_
17	are	_	_	VBP	_	_	_	_	_
18	also	_	_	RB	_	_	_	_	_
19	discussed	_	_	VBN	_	_	_	_	_
20	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	this	_	_	DT	_	_	_	_	_
3	special	_	_	JJ	_	_	_	_	_
4	Issue	_	_	NN	_	_	_	_	_
5	,	_	_	,	_	_	_	_	_
6	we	_	_	PRP	_	_	_	_	_
7	endeavored	_	_	VBD	_	_	_	_	_
8	to	_	_	TO	_	_	_	_	_
9	assemble	_	_	VB	_	_	_	_	_
10	a	_	_	DT	_	_	_	_	_
11	collection	_	_	NN	_	_	_	_	_
12	of	_	_	IN	_	_	_	_	_
13	research	_	_	NN	_	_	_	_	_
14	papers	_	_	NNS	_	_	_	_	_
15	and	_	_	CC	_	_	_	_	_
16	reviews	_	_	NNS	_	_	_	_	_
17	that	_	_	WDT	_	_	_	_	_
18	,	_	_	,	_	_	_	_	_
19	together	_	_	RB	_	_	_	_	_
20	,	_	_	,	_	_	_	_	_
21	will	_	_	MD	_	_	_	_	_
22	offer	_	_	VB	_	_	_	_	_
23	a	_	_	DT	_	_	_	_	_
24	comprehensive	_	_	JJ	_	_	_	_	_
25	view	_	_	NN	_	_	_	_	_
26	on	_	_	IN	_	_	_	_	_
27	new	_	_	JJ	_	_	_	_	_
28	areas	_	_	NNS	_	_	_	_	_
29	of	_	_	IN	_	_	_	_	_
30	research	_	_	NN	_	_	_	_	_
31	pertaining	_	_	VBG	_	_	_	_	_
32	to	_	_	TO	_	_	_	_	_
33	VSGs	_	_	NNPS	_	_	_	_	_
34	.	_	_	.	_	_	_	_	_


1	Majzoub	_	_	NNP	_	_	_	_	_
2	et	_	_	FW	_	_	_	_	_
3	al.	_	_	FW	_	_	_	_	_
4	contributed	_	_	VBD	_	_	_	_	_
5	an	_	_	DT	_	_	_	_	_
6	exciting	_	_	JJ	_	_	_	_	_
7	review	_	_	NN	_	_	_	_	_
8	,	_	_	,	_	_	_	_	_
9	addressing	_	_	VBG	_	_	_	_	_
10	the	_	_	DT	_	_	_	_	_
11	current	_	_	JJ	_	_	_	_	_
12	knowledge	_	_	NN	_	_	_	_	_
13	of	_	_	IN	_	_	_	_	_
14	the	_	_	DT	_	_	_	_	_
15	innate	_	_	JJ	_	_	_	_	_
16	immune	_	_	JJ	_	_	_	_	_
17	pathways	_	_	NNS	_	_	_	_	_
18	involved	_	_	VBN	_	_	_	_	_
19	in	_	_	IN	_	_	_	_	_
20	sensing	_	_	VBG	_	_	_	_	_
21	,	_	_	,	_	_	_	_	_
22	signaling	_	_	VBG	_	_	_	_	_
23	,	_	_	,	_	_	_	_	_
24	and	_	_	CC	_	_	_	_	_
25	inducing	_	_	VBG	_	_	_	_	_
26	ISGs	_	_	NNS	_	_	_	_	_
27	and	_	_	CC	_	_	_	_	_
28	VSGs	_	_	NNS	_	_	_	_	_
29	to	_	_	TO	_	_	_	_	_
30	counter	_	_	VB	_	_	_	_	_
31	viral	_	_	JJ	_	_	_	_	_
32	infections	_	_	NNS	_	_	_	_	_
33	.	_	_	.	_	_	_	_	_


1	Their	_	_	PRP$	_	_	_	_	_
2	manuscript	_	_	NN	_	_	_	_	_
3	specifically	_	_	RB	_	_	_	_	_
4	discussed	_	_	VBD	_	_	_	_	_
5	Toll-like	_	_	NNP	_	_	_	_	_
6	receptors	_	_	NNS	_	_	_	_	_
7	(	_	_	-LRB-	_	_	_	_	_
8	TLRs	_	_	NNS	_	_	_	_	_
9	)	_	_	-RRB-	_	_	_	_	_
10	,	_	_	,	_	_	_	_	_
11	RIG-I-like	_	_	JJ	_	_	_	_	_
12	receptors	_	_	NNS	_	_	_	_	_
13	(	_	_	-LRB-	_	_	_	_	_
14	RLRs	_	_	NNS	_	_	_	_	_
15	)	_	_	-RRB-	_	_	_	_	_
16	,	_	_	,	_	_	_	_	_
17	and	_	_	CC	_	_	_	_	_
18	the	_	_	DT	_	_	_	_	_
19	cGAS-STING	_	_	NNP	_	_	_	_	_
20	pathway	_	_	NN	_	_	_	_	_
21	,	_	_	,	_	_	_	_	_
22	placing	_	_	VBG	_	_	_	_	_
23	their	_	_	PRP$	_	_	_	_	_
24	evolution	_	_	NN	_	_	_	_	_
25	into	_	_	IN	_	_	_	_	_
26	perspective	_	_	NN	_	_	_	_	_
27	in	_	_	IN	_	_	_	_	_
28	diverse	_	_	JJ	_	_	_	_	_
29	organisms	_	_	NNS	_	_	_	_	_
30	and	_	_	CC	_	_	_	_	_
31	the	_	_	DT	_	_	_	_	_
32	dynamic	_	_	JJ	_	_	_	_	_
33	co-evolution	_	_	NN	_	_	_	_	_
34	and	_	_	CC	_	_	_	_	_
35	diversification	_	_	NN	_	_	_	_	_
36	of	_	_	IN	_	_	_	_	_
37	these	_	_	DT	_	_	_	_	_
38	pathways	_	_	NNS	_	_	_	_	_
39	with	_	_	IN	_	_	_	_	_
40	respect	_	_	NN	_	_	_	_	_
41	to	_	_	TO	_	_	_	_	_
42	viral	_	_	JJ	_	_	_	_	_
43	infections	_	_	NNS	_	_	_	_	_
44	.	_	_	.	_	_	_	_	_
45	Liu	_	_	NNP	_	_	_	_	_
46	et	_	_	FW	_	_	_	_	_
47	al.	_	_	FW	_	_	_	_	_
48	discussed	_	_	VBD	_	_	_	_	_
49	the	_	_	DT	_	_	_	_	_
50	mechanisms	_	_	NNS	_	_	_	_	_
51	underlying	_	_	VBG	_	_	_	_	_
52	how	_	_	WRB	_	_	_	_	_
53	herpesviruses	_	_	NNS	_	_	_	_	_
54	can	_	_	MD	_	_	_	_	_
55	be	_	_	VB	_	_	_	_	_
56	detected	_	_	VBN	_	_	_	_	_
57	by	_	_	IN	_	_	_	_	_
58	pattern	_	_	NN	_	_	_	_	_
59	recognition	_	_	NN	_	_	_	_	_
60	receptors	_	_	NNS	_	_	_	_	_
61	(	_	_	-LRB-	_	_	_	_	_
62	PRRs	_	_	NNS	_	_	_	_	_
63	)	_	_	-RRB-	_	_	_	_	_
64	to	_	_	TO	_	_	_	_	_
65	induce	_	_	VB	_	_	_	_	_
66	the	_	_	DT	_	_	_	_	_
67	expression	_	_	NN	_	_	_	_	_
68	of	_	_	IN	_	_	_	_	_
69	interferons	_	_	NNS	_	_	_	_	_
70	(	_	_	-LRB-	_	_	_	_	_
71	IFNs	_	_	NNS	_	_	_	_	_
72	)	_	_	-RRB-	_	_	_	_	_
73	and	_	_	CC	_	_	_	_	_
74	inflammatory	_	_	JJ	_	_	_	_	_
75	cytokines	_	_	NNS	_	_	_	_	_
76	.	_	_	.	_	_	_	_	_


1	They	_	_	PRP	_	_	_	_	_
2	also	_	_	RB	_	_	_	_	_
3	described	_	_	VBD	_	_	_	_	_
4	the	_	_	DT	_	_	_	_	_
5	ability	_	_	NN	_	_	_	_	_
6	of	_	_	IN	_	_	_	_	_
7	herpesviruses	_	_	NNS	_	_	_	_	_
8	to	_	_	TO	_	_	_	_	_
9	establish	_	_	VB	_	_	_	_	_
10	persistent	_	_	JJ	_	_	_	_	_
11	infection	_	_	NN	_	_	_	_	_
12	in	_	_	IN	_	_	_	_	_
13	the	_	_	DT	_	_	_	_	_
14	presence	_	_	NN	_	_	_	_	_
15	of	_	_	IN	_	_	_	_	_
16	active	_	_	JJ	_	_	_	_	_
17	immune	_	_	JJ	_	_	_	_	_
18	responses	_	_	NNS	_	_	_	_	_
19	involving	_	_	VBG	_	_	_	_	_
20	VSGs	_	_	NNS	_	_	_	_	_
21	.	_	_	.	_	_	_	_	_
22	Asmi	_	_	NNP	_	_	_	_	_
23	et	_	_	FW	_	_	_	_	_
24	al.	_	_	FW	_	_	_	_	_
25	reviewed	_	_	VBD	_	_	_	_	_
26	Small	_	_	NNP	_	_	_	_	_
27	Ubiquitin-like	_	_	NNP	_	_	_	_	_
28	Modifier	_	_	NN	_	_	_	_	_
29	(	_	_	-LRB-	_	_	_	_	_
30	SUMO	_	_	NN	_	_	_	_	_
31	)	_	_	-RRB-	_	_	_	_	_
32	protein	_	_	NN	_	_	_	_	_
33	conjugation	_	_	NN	_	_	_	_	_
34	as	_	_	IN	_	_	_	_	_
35	a	_	_	DT	_	_	_	_	_
36	component	_	_	NN	_	_	_	_	_
37	of	_	_	IN	_	_	_	_	_
38	intrinsic	_	_	JJ	_	_	_	_	_
39	and	_	_	CC	_	_	_	_	_
40	innate	_	_	JJ	_	_	_	_	_
41	immunity	_	_	NN	_	_	_	_	_
42	,	_	_	,	_	_	_	_	_
43	specifically	_	_	RB	_	_	_	_	_
44	with	_	_	IN	_	_	_	_	_
45	respect	_	_	NN	_	_	_	_	_
46	to	_	_	TO	_	_	_	_	_
47	rhabdoviruses	_	_	NNS	_	_	_	_	_
48	infection	_	_	NN	_	_	_	_	_
49	and	_	_	CC	_	_	_	_	_
50	in	_	_	IN	_	_	_	_	_
51	relation	_	_	NN	_	_	_	_	_
52	to	_	_	TO	_	_	_	_	_
53	the	_	_	DT	_	_	_	_	_
54	production	_	_	NN	_	_	_	_	_
55	and	_	_	CC	_	_	_	_	_
56	secretion	_	_	NN	_	_	_	_	_
57	of	_	_	IN	_	_	_	_	_
58	interferon	_	_	NN	_	_	_	_	_
59	.	_	_	.	_	_	_	_	_


1	Rhabdoviruses-induced	_	_	JJ	_	_	_	_	_
2	interferon	_	_	NN	_	_	_	_	_
3	production	_	_	NN	_	_	_	_	_
4	and	_	_	CC	_	_	_	_	_
5	the	_	_	DT	_	_	_	_	_
6	activation	_	_	NN	_	_	_	_	_
7	of	_	_	IN	_	_	_	_	_
8	interferon	_	_	NN	_	_	_	_	_
9	signaling	_	_	NN	_	_	_	_	_
10	pathways	_	_	NNS	_	_	_	_	_
11	,	_	_	,	_	_	_	_	_
12	as	_	_	RB	_	_	_	_	_
13	well	_	_	RB	_	_	_	_	_
14	as	_	_	IN	_	_	_	_	_
15	the	_	_	DT	_	_	_	_	_
16	expression	_	_	NN	_	_	_	_	_
17	and	_	_	CC	_	_	_	_	_
18	functions	_	_	NNS	_	_	_	_	_
19	of	_	_	IN	_	_	_	_	_
20	viral	_	_	JJ	_	_	_	_	_
21	restriction	_	_	NN	_	_	_	_	_
22	factors	_	_	NNS	_	_	_	_	_
23	,	_	_	,	_	_	_	_	_
24	are	_	_	VBP	_	_	_	_	_
25	discussed	_	_	VBN	_	_	_	_	_
26	.	_	_	.	_	_	_	_	_
27	Ashley	_	_	NNP	_	_	_	_	_
28	et	_	_	FW	_	_	_	_	_
29	al.	_	_	FW	_	_	_	_	_
30	reported	_	_	VBD	_	_	_	_	_
31	that	_	_	IN	_	_	_	_	_
32	by	_	_	IN	_	_	_	_	_
33	using	_	_	VBG	_	_	_	_	_
34	cells	_	_	NNS	_	_	_	_	_
35	engineered	_	_	VBN	_	_	_	_	_
36	to	_	_	TO	_	_	_	_	_
37	block	_	_	VB	_	_	_	_	_
38	either	_	_	CC	_	_	_	_	_
39	the	_	_	DT	_	_	_	_	_
40	response	_	_	NN	_	_	_	_	_
41	to	_	_	TO	_	_	_	_	_
42	,	_	_	,	_	_	_	_	_
43	or	_	_	CC	_	_	_	_	_
44	production	_	_	NN	_	_	_	_	_
45	of	_	_	IN	_	_	_	_	_
46	,	_	_	,	_	_	_	_	_
47	type-I	_	_	NN	_	_	_	_	_
48	IFN	_	_	NNP	_	_	_	_	_
49	,	_	_	,	_	_	_	_	_
50	the	_	_	DT	_	_	_	_	_
51	regulation	_	_	NN	_	_	_	_	_
52	of	_	_	IN	_	_	_	_	_
53	IFN-independent	_	_	JJ	_	_	_	_	_
54	ISGs	_	_	NNS	_	_	_	_	_
55	was	_	_	VBD	_	_	_	_	_
56	examined	_	_	VBN	_	_	_	_	_
57	in	_	_	IN	_	_	_	_	_
58	the	_	_	DT	_	_	_	_	_
59	context	_	_	NN	_	_	_	_	_
60	of	_	_	IN	_	_	_	_	_
61	human	_	_	JJ	_	_	_	_	_
62	cytomegalovirus	_	_	NN	_	_	_	_	_
63	(	_	_	-LRB-	_	_	_	_	_
64	HCMV	_	_	NN	_	_	_	_	_
65	)	_	_	-RRB-	_	_	_	_	_
66	infection	_	_	NN	_	_	_	_	_
67	.	_	_	.	_	_	_	_	_


1	Several	_	_	JJ	_	_	_	_	_
2	ISGs	_	_	NNS	_	_	_	_	_
3	,	_	_	,	_	_	_	_	_
4	including	_	_	VBG	_	_	_	_	_
5	IFIT1	_	_	NNP	_	_	_	_	_
6	,	_	_	,	_	_	_	_	_
7	IFIT2	_	_	NNP	_	_	_	_	_
8	,	_	_	,	_	_	_	_	_
9	IFIT3	_	_	NNP	_	_	_	_	_
10	,	_	_	,	_	_	_	_	_
11	Mx1	_	_	NNP	_	_	_	_	_
12	,	_	_	,	_	_	_	_	_
13	Mx2	_	_	NNP	_	_	_	_	_
14	,	_	_	,	_	_	_	_	_
15	CXCL10	_	_	NNP	_	_	_	_	_
16	,	_	_	,	_	_	_	_	_
17	and	_	_	CC	_	_	_	_	_
18	ISG15	_	_	NNP	_	_	_	_	_
19	were	_	_	VBD	_	_	_	_	_
20	found	_	_	VBN	_	_	_	_	_
21	to	_	_	TO	_	_	_	_	_
22	be	_	_	VB	_	_	_	_	_
23	upregulated	_	_	VBN	_	_	_	_	_
24	transcriptionally	_	_	RB	_	_	_	_	_
25	following	_	_	VBG	_	_	_	_	_
26	HCMV	_	_	NNP	_	_	_	_	_
27	infection	_	_	NN	_	_	_	_	_
28	independently	_	_	RB	_	_	_	_	_
29	of	_	_	IN	_	_	_	_	_
30	type-I	_	_	NN	_	_	_	_	_
31	IFN	_	_	NNP	_	_	_	_	_
32	.	_	_	.	_	_	_	_	_


1	Furthermore	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	by	_	_	IN	_	_	_	_	_
4	using	_	_	VBG	_	_	_	_	_
5	IRF3	_	_	NNP	_	_	_	_	_
6	knockdown	_	_	NN	_	_	_	_	_
7	CRISPR/Cas-9	_	_	NNP	_	_	_	_	_
8	clones	_	_	NNS	_	_	_	_	_
9	,	_	_	,	_	_	_	_	_
10	they	_	_	PRP	_	_	_	_	_
11	were	_	_	VBD	_	_	_	_	_
12	able	_	_	JJ	_	_	_	_	_
13	to	_	_	TO	_	_	_	_	_
14	demonstrate	_	_	VB	_	_	_	_	_
15	IFN-independent	_	_	JJ	_	_	_	_	_
16	control	_	_	NN	_	_	_	_	_
17	of	_	_	IN	_	_	_	_	_
18	ISG	_	_	NNP	_	_	_	_	_
19	expression	_	_	NN	_	_	_	_	_
20	during	_	_	IN	_	_	_	_	_
21	HCMV	_	_	NNP	_	_	_	_	_
22	infection	_	_	NN	_	_	_	_	_
23	of	_	_	IN	_	_	_	_	_
24	human	_	_	JJ	_	_	_	_	_
25	fibroblasts	_	_	NNS	_	_	_	_	_
26	that	_	_	WDT	_	_	_	_	_
27	is	_	_	VBZ	_	_	_	_	_
28	absolutely	_	_	RB	_	_	_	_	_
29	dependent	_	_	VBN	_	_	_	_	_
30	on	_	_	IN	_	_	_	_	_
31	IRF3	_	_	NNP	_	_	_	_	_
32	activation	_	_	NN	_	_	_	_	_
33	.	_	_	.	_	_	_	_	_


1	Finally	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	He	_	_	PRP	_	_	_	_	_
4	et	_	_	FW	_	_	_	_	_
5	al.	_	_	FW	_	_	_	_	_
6	revealed	_	_	VBD	_	_	_	_	_
7	that	_	_	IN	_	_	_	_	_
8	the	_	_	DT	_	_	_	_	_
9	THO	_	_	NNP	_	_	_	_	_
10	complex	_	_	JJ	_	_	_	_	_
11	subunit	_	_	NN	_	_	_	_	_
12	7	_	_	CD	_	_	_	_	_
13	homolog	_	_	NN	_	_	_	_	_
14	(	_	_	-LRB-	_	_	_	_	_
15	THOC7	_	_	NN	_	_	_	_	_
16	)	_	_	-RRB-	_	_	_	_	_
17	negatively	_	_	RB	_	_	_	_	_
18	regulates	_	_	VBZ	_	_	_	_	_
19	type-I	_	_	NN	_	_	_	_	_
20	IFN	_	_	NN	_	_	_	_	_
21	production	_	_	NN	_	_	_	_	_
22	by	_	_	IN	_	_	_	_	_
23	promoting	_	_	VBG	_	_	_	_	_
24	TBK1	_	_	NN	_	_	_	_	_
25	proteasomal	_	_	JJ	_	_	_	_	_
26	degradation	_	_	NN	_	_	_	_	_
27	that	_	_	WDT	_	_	_	_	_
28	subsequently	_	_	RB	_	_	_	_	_
29	decreases	_	_	VBZ	_	_	_	_	_
30	IRF3	_	_	NNP	_	_	_	_	_
31	activation	_	_	NN	_	_	_	_	_
32	.	_	_	.	_	_	_	_	_


1	Despite	_	_	IN	_	_	_	_	_
2	the	_	_	DT	_	_	_	_	_
3	recent	_	_	JJ	_	_	_	_	_
4	progress	_	_	NN	_	_	_	_	_
5	in	_	_	IN	_	_	_	_	_
6	our	_	_	PRP$	_	_	_	_	_
7	understanding	_	_	NN	_	_	_	_	_
8	of	_	_	IN	_	_	_	_	_
9	these	_	_	DT	_	_	_	_	_
10	host	_	_	JJ	_	_	_	_	_
11	defense	_	_	NN	_	_	_	_	_
12	responses	_	_	NNS	_	_	_	_	_
13	,	_	_	,	_	_	_	_	_
14	much	_	_	RB	_	_	_	_	_
15	more	_	_	JJR	_	_	_	_	_
16	is	_	_	VBZ	_	_	_	_	_
17	left	_	_	VBN	_	_	_	_	_
18	to	_	_	TO	_	_	_	_	_
19	be	_	_	VB	_	_	_	_	_
20	unraveled	_	_	VBN	_	_	_	_	_
21	with	_	_	IN	_	_	_	_	_
22	respect	_	_	NN	_	_	_	_	_
23	to	_	_	TO	_	_	_	_	_
24	the	_	_	DT	_	_	_	_	_
25	regulation	_	_	NN	_	_	_	_	_
26	of	_	_	IN	_	_	_	_	_
27	antiviral	_	_	JJ	_	_	_	_	_
28	responses	_	_	NNS	_	_	_	_	_
29	triggered	_	_	VBN	_	_	_	_	_
30	by	_	_	IN	_	_	_	_	_
31	distinct	_	_	JJ	_	_	_	_	_
32	viral	_	_	JJ	_	_	_	_	_
33	species	_	_	NNS	_	_	_	_	_
34	.	_	_	.	_	_	_	_	_


1	Clearly	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	IFN	_	_	NNP	_	_	_	_	_
4	is	_	_	VBZ	_	_	_	_	_
5	a	_	_	DT	_	_	_	_	_
6	major	_	_	JJ	_	_	_	_	_
7	component	_	_	NN	_	_	_	_	_
8	of	_	_	IN	_	_	_	_	_
9	host	_	_	NN	_	_	_	_	_
10	defense	_	_	NN	_	_	_	_	_
11	responses	_	_	NNS	_	_	_	_	_
12	,	_	_	,	_	_	_	_	_
13	but	_	_	CC	_	_	_	_	_
14	there	_	_	EX	_	_	_	_	_
15	are	_	_	VBP	_	_	_	_	_
16	many	_	_	JJ	_	_	_	_	_
17	ISGs	_	_	NNS	_	_	_	_	_
18	whose	_	_	WP$	_	_	_	_	_
19	antiviral	_	_	JJ	_	_	_	_	_
20	activities	_	_	NNS	_	_	_	_	_
21	remain	_	_	VBP	_	_	_	_	_
22	to	_	_	TO	_	_	_	_	_
23	be	_	_	VB	_	_	_	_	_
24	clarified	_	_	VBN	_	_	_	_	_
25	that	_	_	WDT	_	_	_	_	_
26	can	_	_	MD	_	_	_	_	_
27	be	_	_	VB	_	_	_	_	_
28	regulated	_	_	VBN	_	_	_	_	_
29	independently	_	_	RB	_	_	_	_	_
30	of	_	_	IN	_	_	_	_	_
31	IFN	_	_	NNP	_	_	_	_	_
32	.	_	_	.	_	_	_	_	_


1	These	_	_	DT	_	_	_	_	_
2	new	_	_	JJ	_	_	_	_	_
3	genes	_	_	NNS	_	_	_	_	_
4	would	_	_	MD	_	_	_	_	_
5	likely	_	_	RB	_	_	_	_	_
6	be	_	_	VB	_	_	_	_	_
7	ideal	_	_	JJ	_	_	_	_	_
8	candidates	_	_	NNS	_	_	_	_	_
9	to	_	_	TO	_	_	_	_	_
10	be	_	_	VB	_	_	_	_	_
11	targeted	_	_	VBN	_	_	_	_	_
12	through	_	_	IN	_	_	_	_	_
13	therapeutic	_	_	JJ	_	_	_	_	_
14	intervention	_	_	NN	_	_	_	_	_
15	as	_	_	IN	_	_	_	_	_
16	novel	_	_	JJ	_	_	_	_	_
17	antiviral	_	_	JJ	_	_	_	_	_
18	strategies	_	_	NNS	_	_	_	_	_
19	.	_	_	.	_	_	_	_	_


1	We	_	_	PRP	_	_	_	_	_
2	hope	_	_	VBP	_	_	_	_	_
3	this	_	_	DT	_	_	_	_	_
4	special	_	_	JJ	_	_	_	_	_
5	issue	_	_	NN	_	_	_	_	_
6	provides	_	_	VBZ	_	_	_	_	_
7	a	_	_	DT	_	_	_	_	_
8	wealth	_	_	NN	_	_	_	_	_
9	of	_	_	IN	_	_	_	_	_
10	basic	_	_	JJ	_	_	_	_	_
11	scientific	_	_	JJ	_	_	_	_	_
12	data	_	_	NNS	_	_	_	_	_
13	and	_	_	CC	_	_	_	_	_
14	introduces	_	_	VBZ	_	_	_	_	_
15	new	_	_	JJ	_	_	_	_	_
16	concepts	_	_	NNS	_	_	_	_	_
17	pertaining	_	_	VBG	_	_	_	_	_
18	to	_	_	TO	_	_	_	_	_
19	ISGs	_	_	NNS	_	_	_	_	_
20	that	_	_	WDT	_	_	_	_	_
21	are	_	_	VBP	_	_	_	_	_
22	regulated	_	_	VBN	_	_	_	_	_
23	independently	_	_	RB	_	_	_	_	_
24	of	_	_	IN	_	_	_	_	_
25	IFN	_	_	NNP	_	_	_	_	_
26	signaling	_	_	VBG	_	_	_	_	_
27	.	_	_	.	_	_	_	_	_

